XML 29 R13.htm IDEA: XBRL DOCUMENT
v3.25.2

COMMITMENTS AND CONTINGENCIES | 9 Months Ended
--- | ---
Jun. 30, 2025
COMMITMENTS AND CONTINGENCIES |
COMMITMENTS AND CONTINGENCIES | F. COMMITMENTS AND CONTINGENCIES Clinical Research Agreements In August 2024 the Company entered into an agreement, pursuant to which the Company engaged Ergomed Clinical Research, Inc. to provide clinical development services related to the Company’s upcoming confirmatory registration study in exchange for fees. Since the Company entered into this agreement it has incurred research and development expenses of approximately $0.7 million as of June 30, 2025. Lease Agreements The Company leases a manufacturing facility near Baltimore, Maryland (the San Tomas lease). The building was remodeled in accordance with the Company’s specifications so that it can be used by the Company to manufacture Multikine for the Company’s Phase III clinical trial and sales of the drug if approved by the FDA or regulators in Canada, the UK or Europe. The lease is for a term of twenty years and requires annual base rent to escalate each year at 3%. The Company is required to pay all real estate and personal property taxes, insurance premiums, maintenance expenses, repair costs and utilities. The lease allows the Company, at its election, to extend the lease for two ten-year periods or to purchase the building at the end of the 20-year lease, which expires in October 2028. The renewal options are not included in the calculation of the right-of-use asset and lease liability because exercise of those options is not reasonably certain. As of June 30, 2025 and September 30, 2024, respectively, the net book value of the finance lease right-of-use asset is approximately $6.0 million and $7.4 million and the balance of the finance lease liability is approximately $8.5 million and $10.0 million, of which approximately $2.2 million and $2.0 million is current. These amounts include the San Tomas lease as well as several other smaller finance leases for office equipment. During the nine months ended June 30, 2025 and 2024, the finance right-of-use assets are being depreciated using a straight-line method over the underlying lease terms and depreciation expense totaled approximately $1.4 million in both periods, which is included in research and development expense on the accompanying condensed statements of operations. Total cash paid related to finance leases during the nine months ended June 30, 2025 and 2024, was approximately $2.1 million and $2.0 million, respectively, of which approximately $0.6 million and $0.7 million was for interest, respectively. The total cash paid related to finance lease principal payments is included in cash flows from financing activities on the accompanying condensed statements of cash flows. The total cash paid related to finance lease interest expense is included in cash flows from operating activities on the accompanying condensed statements of cash flows. As of June 30, 2025, the weighted average discount rate of the Company’s finance leases is 8.46% and the weighted average remaining lease term is 3.34 years. During the nine months ended June 30, 2025 and 2024, total finance lease costs were approximately $1.9 million and $2.1 million, respectively, consisting of approximately $1.4 million of lease asset amortization for both periods and approximately $0.6 million and $0.7 million of interest on the finance lease liabilities, respectively. Variable lease expenses, such as maintenance costs, utilities, and real property taxes are not included in right-of-use assets or lease liabilities but rather are expensed as incurred. During the nine months ended June 30, 2025, there were approximately $0.7 million of variable finance lease costs, which are included in research and development expense on the accompanying condensed statements of operations. On January 11, 2023, the Company was required to deposit approximately $2.3 million to its landlord, equivalent to one year’s rent, for falling below the stipulated cash threshold in accordance with the San Tomas lease. The amount will be included as an asset on the balance sheet until the Company meets the minimum cash balance required and the deposit is returned. Approximate future minimum lease payments under finance leases as of June 30, 2025 are as follows:
Three months ending September 30, 2025 |  | $ | 688,000 |
Year ending September 30, |  |  |  |
2026 |  |  | 2,838,000 |
2027 |  |  | 2,929,000 |
2028 |  |  | 3,021,000 |
2029 |  |  | 255,000 |
2030 |  |  | - |
Total future minimum lease obligation |  |  | 9,731,000 |
Less imputed interest on finance lease obligations |  |  | (1,253,000 | )
Net present value of financing lease obligations |  |  | 8,478,000 |
Less net present value of financing lease obligations – current portion |  |  | (2,206,000 | )
Net present value of financing lease obligations – non-current portion |  | $ | 6,272,000 |
The Company leases two facilities under operating leases. The lease for the Company’s office headquarters will expire on November 30, 2025. The lease for its research and development laboratory will expire on February 29, 2032. The operating leases include escalating rental payments. The Company is recognizing the related rent expense on a straight-line basis over the terms of the leases. As of June 30, 2025 and September 30, 2024, respectively, the net book value of the operating lease right-of-use asset is approximately $1.3 million and $1.5 million and the balance of the operating lease liability is approximately $1.5 million and $1.7 million, of which approximately $0.2 million is current in both periods. During the nine months ended June 30, 2025 and 2024, the Company incurred lease expense under operating leases of approximately $0.1 million in both periods, respectively, which is included in general and administrative expense on the accompanying condensed statements of operations. Total cash paid related to operating leases during the nine months ended June 30, 2025 and 2024 was approximately $0.3 million for both periods. The total cash paid related to operating leases is included in cash flows from operating activities on the accompanying condensed statements of cash flows. The weighted average discount rate of the Company’s operating leases is 8.95% and the weighted average the remaining lease term is 6.49 years. As of June 30, 2025, approximate future minimum lease payments on operating leases are as follows:
Three months ending September 30, 2025 |  | $ | 93,000 |
Year ending September 30, |  |  |  |
2026 |  |  | 287,000 |
2027 |  |  | 277,000 |
2028 |  |  | 285,000 |
2029 |  |  | 294,000 |
2030 |  |  | 303,000 |
Thereafter |  |  | 443,000 |
Total future minimum lease obligation |  |  | 1,982,000 |
Less imputed interest on operating lease obligation |  |  | (496,000 | )
Net present value of operating lease obligations |  |  | 1,486,000 |
Less net present value of operating lease obligations – current portion |  |  | (188,000 | )
Net present value of operating lease obligations – non-current portion |  | $ | 1,298,000 |

X
- References No definition available. + Details
Name: | cvm_CommitmentsAndContingenciesAbstract
Namespace Prefix: | cvm_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for commitments and contingencies. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContent Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContent Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details
Name: | us-gaap_CommitmentsAndContingenciesDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration